Efferon Received CE Mark for Pediatric Sepsis Device
The medical technology firm gained approval in April 2026 for its device designed to treat pediatric sepsis cases.
Updated on Oct. 11, 2026 in Children’s Health
Live Poll
Do you trust that medical technology development is sufficiently addressing the urgent needs of children?
Efferon received a CE mark for its pediatric blood purification device, Efferon NEO, in April 2026. The device is now utilized in intensive care units across 30 countries to treat children suffering from sepsis.
Why it matters
Sepsis accounts for approximately 3 million deaths among children under five every year, and this device targets immune system overreactions that are often resistant to standard antibiotic treatments.
Efferon NEO is engineered to accommodate the lower circulating blood volume of children, removing endotoxins and cytokines from the blood. The company projects reaching $2 million in annualized revenue by the end of 2026.
The players
Efferon
This medical technology company focuses on developing advanced blood purification systems.
Moscow State University
This institution serves as the academic origin point where scientists initially developed the purification technology.
The details
The technology, which originated from research at Moscow State University, functions as a multimodal purification system. It operates within intensive care units to manage life-threatening inflammatory responses that occur when an immune system overreacts.
Timeline
Efferon NEO received a CE mark in April 2026.
Efferon expects to reach $2 million in annualized revenue by the end of 2026.
Health Landscape
The introduction of specialized pediatric purification tools marks a shift toward customized critical care technology that moves beyond general adult treatment protocols. This development mirrors the evolution of medical interventions that address specific patient needs during intensive care.
The availability of this device in intensive care units provides clinicians with an option to treat severe sepsis symptoms where antibiotics fail. This expands the range of critical support available to children in medical facilities across 30 countries.
The takeaway
Advancements in blood purification technology are crucial for addressing complex immune responses in young patients. Healthcare providers in intensive care settings can now utilize these specific tools to better manage the physical complications associated with childhood sepsis.
Further reading
Learn more about the latest innovations in Children’s Health.
Live Poll
Do you trust that medical technology development is sufficiently addressing the urgent needs of children?
